ProShares Ultra Cloud Computing (NASDAQ: SKYU)

Últimas noticias sobre ProShares Ultra Cloud Computing (NASDAQ:SKYU)

Technology

Consumer Cyclical

Other

Communication Services

Healthcare

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is constructed and maintained by Nasdaq Inc. The Index is comprised of companies classified as cloud computing companies by the Consumer Technology Association. CTA classifies companies as cloud computing if the company is engaged in one or more activities.

Oracle Corp.

Arista Networks Inc.

International Business Machines Corp.

Amazon.Com Inc

Microsoft Corp

Pure Storage Inc

ProShares Ultra Nasdaq Cloud Computing ETF

ProShares Ultra Cloud Computing

WIIM

INDP

Indaptus Therapeutics shares are trading higher after the company started a Phase 1 combination study of Decoy20 with BeiGene's cancer drug for advanced solid tumors.

General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) will release its third-quarter financial results, before the <a href="https://www.benzinga.com/quote/GIS/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the company to report quarterly earnings at 96 cents per share, down from $1.17 per share in the year-ago period. General Mills projects quarterly revenue of $4.95 billion, compared to $5.1 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around General Mills, some investors may be eyeing potential gains from the company's dividends, too. Currently, General Mills offers an annual dividend yield of 3.94%. That&#8217;s a quarterly dividend of 60 cents per share ($2.40 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $152,350 or around 2,500 shares. For a more modest $100 per month or $1,200 per year, you would need $30,470 or around 500 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.40 in this case). So, $6,000 / $2.40 = 2,500 ($500 per month), and $1,200 / $2.40 = 500 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of General Mills gained 2.3% to close at $60.94 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

News

Markets

How To Earn $500 A Month From General Mills Stock Ahead Of Q3 Earnings

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) announced it advanced to&nbsp;a new expansion arm of its Phase 1b/2 clinical <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">trial of Decoy20</a>.
The expansion will evaluate the combination of Decoy20 with BeiGene Ltd's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early signs of anti-tumor activity.
<ul>
<li>Initial participants will first receive one week of Decoy20 monotherapy intravenously before starting the combination treatment with Decoy20 + tislelizumab. </li>
<li>The first few patients in the combination phase will be enrolled sequentially to monitor safety. </li>
<li>After review by the trial's Safety Review Committee, unrestricted enrollment will begin. </li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362322/butterfly-network-is-pioneering-digital-ultrasound-market-analyst-says-undervalued-stock-could-rise-with-growth-execution" rel="noreferrer noopener">Butterfly Network Is ‘Pioneering Digital Ultrasound Market,' Analyst Says Undervalued Stock Could Rise With Growth Execution</a>
Participants will receive both treatments for up to one year or until disease progression, unacceptable toxicity, or withdrawal from the study.
Jeffrey Meckler, CEO of Indaptus, commented, "This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time."
The company says checkpoint inhibitors such as tislelizumab have improved outcomes in various cancers, but many patients still do not respond or ultimately do not experience a long-lasting effect.
Decoy20 is engineered to activate the immune system in a manner that is theorized to significantly enhance and broaden the effectiveness of checkpoint inhibitors.
As of December 31, 2024, the company had cash and cash equivalents of $5.8 million. In January 2025, the company conducted a private placement, resulting in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44299019/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corp" rel="noreferrer noopener">net proceeds of $2.0 million</a>.
In February 2025, the company established a $20 million equity line of credit with Yorkville.
The company expects its current cash and cash equivalents to support its ongoing operating activities into the second quarter of 2025.&nbsp;
Price Action: At the last check on Tuesday, INDP stock was down 3.67% at $0.78 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" target="_blank" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

EXCLUSIVE: Indaptus Therapeutics Tells Benzinga 'New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors'

EXCLUSIVE: Indaptus Therapeutics Tells Benzinga Co. Initiates Phase I Combination Study Of Decoy20 With PD-1 Checkpoint Inhibitor Tislelizumab

Barrington Research analyst James Goss maintains Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) with a Outperform and maintains $15 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Townsquare Media, Maintains $15 Price Target

Needham analyst Quinn Bolton reiterates Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Buy and maintains $16 price target.

Reiteration

CRNC

Needham Reiterates Buy on Cerence, Maintains $16 Price Target

<a href="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html" title="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html">https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html</a>

TSLA

CNBC: 'Tesla's China rival Zeekr to roll out advanced driver assistance-system for free'

William Blair analyst Y Katherine Xu downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform.

Downgrades

INCY

William Blair Downgrades Incyte to Market Perform

MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings Misses

INKT

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.09 by 711.11 percent. This is a 153.68 percent increase over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $437.822 million which beat the analyst consensus estimate of $424.001 million by 3.26 percent. This is a 14.12 percent decrease over sales of $509.784 million the same period last year.

Earnings Beats

IHS Holding Q4 2024 GAAP EPS $0.73 Beats $0.09 Estimate, Sales $437.822M Beat $424.001M Estimate

<ul>
<li>The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repayment, satisfaction, and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs, and expenses relating to the offering of the Notes and Credit Agreement transactions described below and/or (iii) for general corporate purposes. The Notes offering is subject to market and other conditions, and may not occur as described or at all.</li>
<li>The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company's revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to $200 million (resulting in aggregate commitments of up to $500 million). The terms of the commitments and loans under the amended revolving credit facility are expected to be substantially similar to those relating to the commitments and loans under the existing revolving credit facility, except with respect to the aggregate amount of commitments thereunder, the maturity date thereof and certain other terms. The Credit Agreement amendments are subject to market and other conditions, and may not occur as described or at all. The consummation of the Notes offering is not conditioned on the consummation of the Credit Agreement amendments and the consummation of the Credit Agreement amendments are not conditioned on the consummation of the Notes offering</li>
</ul>

Financing

PODD

Insulet Intends To Offer $450M Principal Amount Of Senior Unsecured Notes Due 2033 In A Private Placement

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Guidance

USEA

United Maritime Says Long-term Fundamentals Of Dry Bulk Market Remain Strong

PYXS

As Of December 31, 2024, Pyxis Oncology Had Cash And Cash Equivalents Of $128.4M That Is Expected To Provide Cash Runway Into The Second Half Of 2026

Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announces $108 price target.

PCAR

UBS Downgrades PACCAR to Neutral, Announces $108 Price Target

NCNO

Sandbox Banking's Glyue Introduced In The Zoom App Marketplace

United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.41) by 80.49 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $10.80 million which beat the analyst consensus estimate of $9.50 million by 13.68 percent. This is a 6.90 percent decrease over sales of $11.60 million the same period last year.

United Maritime Q4 2024 Adj EPS $(0.08) Beats $(0.41) Estimate, Sales $10.80M Beat $9.50M Estimate

VRAX

Virax Biolabs Enrolls First Patients In Its UK Based Clinical Study Assessing T Cell Dysfunction In Post-acute Infection Syndromes

ProShares Ultra Nasdaq Cloud Computing ETF 2x Shares

Comments

ProShares Ultra Cloud Computing

Noticias

Últimas noticias sobre ProShares Ultra Cloud Computing (NASDAQ:SKYU)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL